文献速递重症综合管理与镇静镇痛

右美托咪定或可乐定镇静与丙泊酚比较:A2B随机临床试验

Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01
一句话结论在ICU机械通气患者中,右美托咪定或可乐定为基础镇静与丙泊酚相比,均未缩短成功拔管时间。

A2B实用、开放标签随机临床试验在英国41个ICU纳入1404例成人机械通气患者,比较右美托咪定或可乐定为基础镇静与丙泊酚(常规)对成功拔管时间的影响。结果显示,右美托咪定vs丙泊酚的亚分布HR为1.09(95%CI 0.96-1.25;P=0.20),可乐定vs丙泊酚为1.05(95%CI 0.95-1.17;P=0.34),均未达统计学显著。右美托咪定和可乐定组躁动及严重心动过缓发生率均高于丙泊酚组,180天死亡率相似。结论认为两种α2受体激动剂为基础镇静均不优于丙泊酚。

要点

  • 右美托咪定(n=457)vs丙泊酚(n=471)成功拔管亚分布HR 1.09(95%CI 0.96-1.25;P=0.20),未达统计学显著。
  • 可乐定(n=476)vs丙泊酚(n=471)成功拔管亚分布HR 1.05(95%CI 0.95-1.17;P=0.34),未达统计学显著。
  • 随机化至成功拔管中位时间:右美托咪定136小时(95%CI 117-150)、可乐定146小时(95%CI 124-168)、丙泊酚162小时(95%CI 136-170)。
  • 与丙泊酚相比,右美托咪定组躁动RR 1.54(95%CI 1.21-1.97)、可乐定组RR 1.55(95%CI 1.22-1.97);严重心动过缓(心率<50/min)右美托咪定RR 1.62(95%CI 1.36-1.93)、可乐定RR 1.58(95%CI 1.33-1.88)。
  • 180天死亡率:右美托咪定vs丙泊酚HR 0.98(95%CI 0.77-1.24),可乐定vs丙泊酚HR 1.04(95%CI 0.82-1.31)。

适用人群与场景

  • 英国41个ICU收治的成人患者,开始机械通气48小时内、正在使用丙泊酚加阿片类药物镇静镇痛、预期机械通气≥48小时。
  • 插管至随机化中位时间21.0小时(IQR 13.2-31.3)。
  • 招募时间2018年12月至2023年10月,末次随访2023年12月10日。

诊断标准与关键阈值

  • 床旁算法目标Richmond躁动-镇静量表(RASS)评分-2至1,除非临床医生要求更深镇静。

处置流程与药物剂量

  • 右美托咪定或可乐定为基础镇静组按算法向上滴定,丙泊酚组向下滴定后主要使用所分配镇静药(右美托咪定或可乐定)。
  • 需要时允许补充使用丙泊酚。

研究设计与关键结果

  • 实用、开放标签随机临床试验,41个ICU,分析人群1404例(平均年龄59.2岁[SD 14.9],男性901例[64%],平均APACHE II评分20.3[SD 8.2])。
  • 主要终点随机化至成功拔管时间:右美托咪定(n=457)vs丙泊酚(n=471)亚分布HR 1.09(95%CI 0.96-1.25;P=0.20);可乐定(n=476)vs丙泊酚(n=471)亚分布HR 1.05(95%CI 0.95-1.17;P=0.34)。
  • 随机化至成功拔管中位时间:右美托咪定136小时(95%CI 117-150)、可乐定146小时(95%CI 124-168)、丙泊酚162小时(95%CI 136-170)。
  • 预设亚组分析中,与年龄、脓毒症状态、中位序贯器官衰竭评估评分或中位谵妄风险评分无交互作用。
  • 次要终点:躁动发生率右美托咪定vs丙泊酚RR 1.54(95%CI 1.21-1.97)、可乐定vs丙泊酚RR 1.55(95%CI 1.22-1.97);严重心动过缓(心率<50/min)右美托咪定vs丙泊酚RR 1.62(95%CI 1.36-1.93)、可乐定vs丙泊酚RR 1.58(95%CI 1.33-1.88)。
  • 180天死亡率:右美托咪定vs丙泊酚HR 0.98(95%CI 0.77-1.24),可乐定vs丙泊酚HR 1.04(95%CI 0.82-1.31)。

证据类型、等级与局限

  • 证据类型:实用、开放标签随机临床试验(RCT)。
  • 结论:在危重患者中,右美托咪定和可乐定在缩短成功拔管时间方面均不优于丙泊酚。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于预期机械通气≥48小时的ICU成人,以右美托咪定或可乐定为基础镇静未显示比丙泊酚缩短成功拔管时间。
  • 使用右美托咪定或可乐定时需注意躁动(RR约1.54-1.55)和严重心动过缓(心率<50/min,RR约1.58-1.62)发生率高于丙泊酚。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Whether α2-adrenergic receptor agonist-based sedation, compared with propofol-based sedation, reduces time to extubation in patients receiving mechanical ventilation in the intensive care unit (ICU) is uncertain.

OBJECTIVE: To evaluate whether dexmedetomidine- or clonidine-based sedation reduces duration of mechanical ventilation compared with propofol-based sedation (usual care).

DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, open-label randomized clinical trial conducted at 41 ICUs in the UK including adults who were within 48 hours of starting mechanical ventilation, were receiving propofol plus an opioid for sedation and analgesia, and were expected to require mechanical ventilation for 48 hours or longer. The median time from intubation to randomization was 21.0 (IQR, 13.2-31.3) hours. Recruitment occurred from December 2018 to October 2023; the last follow-up occurred on December 10, 2023.

INTERVENTIONS: The bedside algorithms used targeted a Richmond Agitation-Sedation Scale score of -2 to 1 (unless clinicians requested deeper sedation). The algorithms supported uptitration in the dexmedetomidine- and clonidine-based sedation intervention groups and supported downtitration for propofol-based sedation followed by sedation primarily with the allocated sedation (dexmedetomidine or clonidine). If required, supplemental use of propofol was permitted.

MAIN OUTCOMES AND MEASURES: The primary outcome was time from randomization to successful extubation. The secondary outcomes included mortality, sedation quality, rates of delirium, and cardiovascular adverse events.

RESULTS: Among the 1404 patients in the analysis population (mean age, 59.2 [SD, 14.9] years; 901 [64%] were male; and the mean APACHE II score was 20.3 [SD, 8.2]), the subdistribution hazard ratio (HR) for time to successful extubation was 1.09 (95% CI, 0.96-1.25; P = .20) for dexmedetomidine (n = 457) vs propofol (n = 471) and was 1.05 (95% CI, 0.95-1.17; P = .34) for clonidine (n = 476) vs propofol (n = 471). The median time from randomization to successful extubation was 136 (95% CI, 117-150) hours for dexmedetomidine, 146 (95% CI, 124-168) hours for clonidine, and 162 (95% CI, 136-170) hours for propofol. In the predefined subgroup analyses, there were no interactions with age, sepsis status, median Sequential Organ Failure Assessment score, or median delirium risk score. Among the secondary outcomes, agitation occurred at a higher rate with dexmedetomidine vs propofol (risk ratio [RR], 1.54 [95% CI, 1.21-1.97]) and with clonidine vs propofol (RR, 1.55 [95% CI, 1.22-1.97]). Compared with propofol, the rates of severe bradycardia (heart rate <50/min) were higher with dexmedetomidine (RR, 1.62 [95% CI, 1.36-1.93]) and clonidine (RR, 1.58 [95% CI, 1.33-1.88]). Compared with propofol, mortality was similar over 180 days for dexmedetomidine (HR, 0.98 [95% CI, 0.77-1.24]) and clonidine (HR, 1.04 [95% CI, 0.82-1.31]).

CONCLUSIONS AND RELEVANCE: In critically ill patients, neither dexmedetomidine nor clonidine was superior to propofol in reducing time to successful extubation.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03653832.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Walsh TS, Parker RA, Aitken LM, et al. Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial. JAMA. 2025. PMID: 40388916. doi:10.1001/jama.2025.7200

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。